Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
_____________ PRST STD US Postage PAID Miami, FL Permit No. 1429 Meetings, Events and Conference Coordinators, Inc. P.O. Box 430376 Miami, FL 33243-0376 14TH ANNUAL MIAMI CANCER MEETING (MCM): “From Chemotherapy to Targeted Therapy, Immunotherapy and Beyond!” January 20-22, 2017 Conrad Hilton Hotel Miami, Florida 14TH ANNUAL MIAMI CANCER MEETING (MCM): “From Chemotherapy to Targeted Therapy, Immunotherapy and Beyond!” January 20-22, 2017 Conrad Hilton Hotel Miami, Florida Program Directors Luis E. Raez, M.D, FACP, FCCP Chief of Hematology-Oncology & Medical Director Memorial Cancer Institute Memorial Health Care System Clinical Associate Professor of Medicine Herbert Wertheim College of Medicine Florida International University Miami, Florida Co-Sponsored by: Florida Society of Clinical Oncology Caio Max S. Rocha Lima, M.D. Hematology and Oncology Associate Cancer Center Director for Translational Research Gibbs Cancer Center & Research Institute CMO Guardian Research Network Spartanburg Healthcare System Spartanburg, SC Edgardo S. Santos Castillero, M.D., FACP Medical Director of Cancer Research Thoracic and Head and Neck Cancer Programs Eugene & Christine Lynn Cancer Institute Associate Professor of Clinical Biomedical Science Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, FL Educational Committee Jumana Ashy, M.S, Pharm.D Eileen Butler, RN, MSN. OCN, CPHON, BMTCN Gerardo Colon-Otero, MD Dina Dumercy, Pharm.D., BCOP Primo Lara, M.D. Jessica MacIntrye, ARNP, NP-C Eduardo Sotomayor, MD Sponsored by: The Medical Educator Consortium Educational Committee • Distinguished Faculty Educational Committee Jumana Ashy, M.S, Pharm.D Eileen Butler, RN, MSN. OCN, CPHON, BMTCN Gerardo Colon-Otero, MD Dina Dumercy, Pharm.D., BCOP Primo Lara, M.D. Jessica MacIntrye, ARNP, NP-C Eduardo Sotomayor, MD Distinguished Faculty Jaffer A. Ajani, M.D. Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences The University of Texas MD Anderson Cancer Center Houston, TX Scott J. Antonia, M.D., Ph.D. Department Chair of the Thoracic Oncology Department H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. Professor of Oncologic Sciences University of South Florida College of Medicine Tampa, FL Jumana Ashy, M.S, Pharm.D Clinical Pharmacist Pediatric Hematology-Oncology Clinic and Infusion Center University of Miami, Miller School of Medicine Miami, FL Denisse Bretel, MD Medical Director, GECO (Peruvian Oncology Research Group) Lima, Peru Eileen Bulter, RN, MSN. OCN, CPHON, BMTCN University of Miami Miller School of Medicine Miami, FL Gerardo Colon-Otero, M.D. Associate Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic, Jacksonville, FL Dina Dumercy, Pharm.D.,BCOP Clinical Coordinator Oncology Memorial Cancer Institute Pharmacy Department Memorial Healthcare System Hollywood, FL Barbara J. Gilitz, M.D. Associate Professor of Medicine, USC Keck School of Medicine Los Angeles, CA Sergio A. Giralt, M.D. Chief, Adult Bone Marrow Transplant Service; Melvin Berlin Family Chair in Multiple Myeloma Memorial Sloan Kettering Cancer Center New York, NY Brian Hunis, M.D. Caio Max S. Rocha Lima, M.D. Hematology and Oncology Associate Cancer Center Director for Translational Research Gibbs Cancer Center & Research Institute CMO Guardian Research Network Spartanburg Healthcare System Spartanburg, SC Director of Head & Neck Cancer and Quality Memorial Cancer Institute Clinical Associate Professor of Medicine Herbert Wertheim College of Medicine Florida International University Hollywood, FL Head of Unit Phase I - Early Clinical Trials Director of Clinical Trial Management Program Oncology Department University Hospital Antwerp, Belgium Alan Koletsky, M.D. Hope Rugo, M.D. Affiliate Assistant Professor of Clinical Biomedical Science Charles E. Schmidt College of Medicine Florida Atlantic University Genitourinary Cancer Research Program Lynn Cancer Institute Boca Raton, FL Christian Rolfo Cervetto, M.D., PhD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco, CA Edgardo S. Santos Castillero, M.D., FACP Professor of Medicine, UC Davis School of Medicine Acting Director, UC Davis Comprehensive Cancer Center Sacramento CA Medical Director of Cancer Research Lynn Cancer Institute Thoracic and Head and Neck Cancer Programs Associate Professor of Clinical Biomedical Sciences Florida Atlantic University Boca Raton, Florida Jose Lutzky, M.D. Eduardo Sotomayor, M.D. Jessica MacIntyre, ARNP, NP-C Martin S. Tallman M.D. Eriberto Marques Jr., M.D. Vicente Valero, M.D. Primo N. Lara, Jr., M.D. Co-Chief, Hematology & Oncology Director, Mount Sinai Melanoma Program Mount Sinai Medical Center Miami, FL Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, FL Medical Director of Santa Agueda Hospital Department of Medical Oncology Member of SBOC/SLACOM Recife-PE, Brazil Taofeek K Owonikoko, M.D., Ph.D. Director, Thoracic Oncology Program Assistant Professor Emory School of Medicine Atlanta, GA Luis E. Raez, M.D, FACP, FCCP Chief of Hematology-Oncology & Medical Director Memorial Cancer Institute Memorial Health Care System Clinical Associate Professor of Medicine Herbert Wertheim College of Medicine Florida International University Miami, Florida Director, George Washington University Cancer Center Professor of Medicine, George Washington University School of Medicine & Health Sciences Washington, DC Chief of Leukemia Service Memorial Sloan Kettering Cancer Center New York, NY Professor, and Deputy Chairman, Breast Medical Oncology Department Clinical Director, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic Associate Director, Nellie B. Connally Breast Center The University of Texas M. D. Anderson Cancer Center Houston, TX Adrienne M. Vazquez, MSN, ACNP-BC, AOCN Memorial Sloan Kettering Cancer Center New York, NY 13th Annual Miami Cancer Meeting (MCM): “New Horizons in Treating Patients with Cancer: The Saga of Personalized Medicine” CONFERENCE DESCRIPTION (i.e., NSCLC, head and neck, prostate cancer, and others). This is a three-day conference designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, physician assistants (PA), advanced registered nurse practitioners (ARNP), oncology nurses, registered pharmacists, pharmacy technicians, and radiation therapists. General practitioners (internal medicine and family medicine) will have the benefit of review standard of care and new developments in cancer management. Residents in training and fellows from these specialties are encouraged to attend. 4) Management of adverse events from the use of novel immunotherapy and targeted therapy agents. This year, a depth discussion in immunotherapy for multiple tumor types will take place. Immunotherapy in Oncology is changing the landscape of therapy for different solid tumors such as lung cancer, bladder, kidney, melanoma, and others. Also, topics in solid tumors and hematological malignancies such as breast cancer, lung cancer, gastrointestinal (GI) malignancies, genitourinary (GU) cancers, gynecologic malignancies, head and neck cancers, melanoma, multiple myeloma, CLL and nonHodgkin’s lymphoma, and myelodysplastic syndrome will be reviewed. There will also be a special session devoted to the area of supportive care in oncology, with emphasis on bone metastasis, malignant hypercalcemia, and management of chemotherapy, targeted therapy and immunotherapyrelated side effects. The areas of focus for this conference will include the current standards of care in the treatment of all aforementioned malignancies and new developments in these areas of cancer care. There will be much emphasis on molecular diagnosis and individualization of cancer therapy based on molecular profiles. There will be reviews of new chemotherapeutic agents, new antiangiogenic agents and new immunotherapeutic agents. Presentations from latest national (AACR 2016, ASCO 2016 and ASH 2016) and international forums (ESMO 2016 and WCLC 2016) meetings will be discussed and guidelines of cancer care will be emphasized. The participants in the meeting will have the opportunity not only to learn, review, and understand the state-of-the-art management in cancer care but also engage in personal interaction with our panel of experts in these subjects during our question and answer sessions. CONFERENCE OBJECTIVES Upon completion of this course attendees will be able to: 1) Understand the latest advances in chemotherapy, targeted therapy and immunotherapy options available for lung cancer, breast cancer, GI malignancies, GU malignancies, melanoma, brain tumors, head and neck cancer as well as hematological malignancies including multiple myeloma, NHL, MDS, and CLL. 2) Evaluate the current standards of care in the treatment of a variety of solid and hematologic malignancies. 3) Discuss risks and benefits when combined modality of treatment (that includes radiation therapy and surgery) is delivered to patients who have localized malignant processes 5) Management of complications and symptoms induced by chemotherapy, immunotherapy or targeted therapy including nausea, vomiting, hematologic toxicities (e.g., anemia, neutropenia) and others. ACCREDITATION The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CREDIT HOURS (CME) The Medical Educator Consortium, designates this live activity for a maximum of 15.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. NURSING CEU Continuing Education Credit for Nurses will be awarded by the University of Miami Nursing Education Department. A total of 15 CEU’s will be awarded for attendance to all three days of the conference. Participants may attend separately on Friday for 2.1 credit hours, Saturday for 8.4 credit hours, and Sunday 4.5. A certificate of completion will be provided to each participant at the end of the conference. Credit will be entered into CE Broker. PHARMACY CEU This activity is approved for a total of 15 contact hours of Continuing Education Credit for Pharmacists and Pharmacy Technicians awarded by the University of Miami Sylvester Comprehensive Cancer Center. Participants must attend all day lectures to receive credit for that day. Partial credits are not available. Where credits are approved on a sessionby-session basis, participants must attend each session in its entirety to receive complete credit for the session.. A certificate of completion will be provided to each participant at the end of the conference. Credit will be entered into CE Broker. UMHC/Sylvester is a approved by the Florida Board of Pharmacy as a provider of continuing pharmacy education. “Partial Credit are available”. FACULTY DISCLOSURE STATEMENT The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity. 14th Annual Miami Cancer Meeting (MCM): “New “From Chemotherapy to Targeted Therapy, Immunotherapy and Beyond!” PROGRAM AGENDA Friday, January 20, 2017 : 5:00 pm – 7:30 pm Registration & Visit Exhibits 5:30 pm – 5:40 pm Welcome and Introduction 5:40 pm – 7:50 pm Supportive Care and Palliative Therapy Session Luis E. Raez . Moderator: Dina Dumercy 5:40 pm – 6:10 pm Management of Immunotherapy-Induced Disorders (pneumonitis, colitis, thyroid disorders, skin rash, and others). 6:10 pm – 6:40 pm Cancer Therapy-Induced Bone Loss and Malignant Hypercalcemia. Eriberto Marques, Jr. 6:40 pm – 7:10 pm Nausea and Vomiting: Novel advances in Emesis Management. Jessica MacIntyre 7:10 pm – 7:40 pm Keynote Speaker: The Evolution of Lung Cancer Therapy in the Last Decade: “From Chemotherapy to Targeted Therapy, Immunotherapy and Beyond!” Christian Rolfo 7:40 pm – 7:50 pm Round Table Discussion and Q & A Session. 8:00 pm – 9:00 pm Dinner & Learn Symposia (non CME) Adrienne Vazquez Speakers: MacIntyre, Vazquez, Marques, and Rolfo. Saturday, January 21, 2017 7:00 am – 6:00 pm Registration & Visit Exhibits 7:40 am – 8:40 am Breakfast & Learn Symposium (non CME) 8:40 am – 10:40 am Immunotherapy Session 1 Malignant Diseases: The New Targets of Immunotherapy. Moderator: Luis E. Raez 8:40 am – 9:20 am Immunotherapy in Lung Cancer. Scott Antonia 9:20 am – 10:00 am Immunotherapy in Genitourinary Cancers. Alan Koletsky Immunotherapy in Melanoma. Jose Lutzky 10:00 am – 10:40 am 10:40 am – 11:00 am Coffee Break & Visit Exhibits 11:00 am – 1:00 am Immunotherapy Session 2 Malignant Diseases: The New Targets of Immunotherapy. Moderator: Brian Hunis 11:00 am – 11:40 pm Immunotherapy in Head and Neck Cancer. Edgardo S. Santos 11:40 am – 12:20 pm Immunotherapy in Breast and Gynecologic Malignancies. Gerardo Colon-Otero 12:20 pm – 12:50 pm Is it PDL-1 the Biomarker? Mutation Burden? Or What is the Best Biomarker for Lung Cancer Immunotherapy? Taofek Owonikoko 12:50 pm – 1:00 pm Round Table Discussion and Q & A Session. 1:00 pm – 2:00 pm Lunch & Learn Symposia (non-CME) 2:00 pm – 2:20 pm Coffee Break and Visit Exhibits 09:10 am – Speakers: Santos, Colon-Otero, Owonikoko and Hunis PROGRAM AGENDA Continued... 2:20 pm – 4:00 pm Genitourinary Malignancy Session Moderator: Edgardo S. Santos 2:20 pm – 3:00 pm Tyrosine Kinase Inhibitors and Other Pathways in Renal Cell Carcinoma. Primo N. Lara, Jr. 3:00 pm – 3:40 pm Novel Pathways and Genomics in the Management of Prostate Cancer. Alan Koletsky 3:40 pm – 3:50 pm Round Table Discussion and Q & A Session. Speakers: Lara, Koletsky and Santos 3:50 pm – 4:00 pm Coffee Break & Visit Exhibits 4:00 pm – 5:40 pm Hematology Malignancies Session Moderator: Eduardo M. Sotomayor 4:00: pm – 4:30 pm Immunotherapy and Targeted Therapy in Multiple Myeloma. Sergio Giralt 4:30 pm – 5:00 pm Targeted Therapy for B- and T-Cell Non-Hodgkin’s Lymphomas. Eduardo M. Sotomayor 5:00 pm – 5:30 pm High Risk Myelodysplasia and Acute Leukemias. Martin Tallman 5:30 pm – 6:00 pm Round Table Discussion and Q & A Session. Speakers: Giralt, Sotomayor, Tallman Sunday, January 22, 2017 7:00 am – 3:10 am Registration &Visit Exhibits 7:40 am – 8:40 am Breakfast & Learn Symposia (non CME) 8:40 am – 9:50 am Gastrointestinal Malignancy Session Moderator: Caio Max Rocha-Lima 8:40 am – 9:10 am Novel Advances in Treatment of Gastric Cancers and Pancreatobiliary Malignancies. Caio Max Rocha Lima 9:10 am – 9:40 am Genomics and New Insights of Colorectal Cancer. Jaffe Ajani 9:40 am – 9:50 am Round Table Discussion and Q & A session Speakers: Ajani and Rocha-Lima 9:50 am – 10:20 am Thyroid Malignancies. Brian Hunis 10:20 am – 10:40 am Coffee Break & Visit Exhibits 10:40 am – 12:40 pm Lung Cancer Session Moderator: Edgardo S. Santos 10:40 am – 11:10 am EGFR, ALK and ROS-1 in Lung Cancer. Luis E. Raez 11:10 am – 11:40 am Other Novel Pathways in Lung Cancer (MET, RET, NTRK, BRAF) and Antiangiogenic Agents. Barbara Gitlitz 11:40 am – 12:10 pm Where are we now in Squamous-NSCLC and Small Cell Lung Cancer? Edgardo S. Santos 12:10 pm – 12:30 pm Round Table Discussion and Q & A Session. Speakers: Gitlitz, Raez & Santos 12:30 pm – 1:40 pm Lunch & Learn Symposia 1:40 pm – 3:15 pm Breast Cancer Section Moderator: Denisse Bretel 1:40 pm – 2:20 pm Anti-HER2 Therapies in Breast Cancer: Adjuvant and Neoadjuvant. Hope Rugo 2:20 pm – 3:00 pm Chemotherapy and Hormonal Therapy in the Metastatic Setting. (non Her2 therapy) Vicente Valero 3:00 pm – 3:10 pm Round Table Discussion and Q & A Session. Speakers: Rugo, Valero, and Bretel 3:10 pm Meeting Adjourn and Closing Remarks REGISTRATION HOTEL INFORMATION Fees: $250 - Physicians $100 - Residents, Fellows, Nurses & Allied Health Professionals $300 - Industry Professionals The Conrad Hilton Hotel Miami 1395 Brickell Avenue Miami, FL 33131 Telephone: 305-503-6585 Website: http://conradhotels1.hilton.com Registration fee includes all day admission to the Friday evening, Saturday, and Sunday scientific presentations. Refunds must be provided in writing prior to December 20th, 2016 no Refunds will be provided. Prior to the December 20th deadline any cancellation will include a $50 administrative charge. Register online at www.meccinc.com Discover the luxury of the Conrad Miami, the premier hotel in South Florida, combining the ultimate hotel service and the latest technological advancements with the fashion sensibilities of downtown Miami. Located in the innovatively designed structure of concave glass and steel, in the heart of the city’s financial district, the Conrad Miami hotel overlooks Biscayne Bay in Florida.The Conrad Miami has quick and easy access to many attractions in downtown Miami, including South Beach, Coconut Grove and Key Biscayne and is also just 15 minutes from the Miami International Airport. Register online at www.meccinc.com CONFERENCE MANAGEMENT MECC (Meetings Events & Conference Coordinators, Inc.) 6619 S Dixie Highway #341, Miami, FL 33143 Telephone 305/663-1628 Office Fax 305/675-2718 The hotel is offering special rates during this conference of $315 Deluxe City View; $345 Deluxe Bay View plus tax, European plan (no meals). The cut of date to make reservations is January 4, 2017, after this date reservations are subject to hotel availability. Make your reservations by calling 1-800-CONRADS and identify you as attending the “Miami Cancer Meeting” group code “AMC ” or using the link https://resweb.passkey.com/go/MCM2017 Or visit our website at www.meccinc.com REGISTRATION FORM 14th Annual Miami Cancer Meeting (MCM): “From Chemotherapy to Targeted Therapy, Immunotherapy and Beyond!” January 20-22, 2017 Conrad Hilton Hotel, Miami, FL Register online at www.meccinc.com or FAX to 305/675-2718. Name __________________________________________________________________________ Degree __________________________ Address ___________________________________________________________________________________________________________ City _________________________________________________ State ______________________ Zip _____________________________ Telephone (_____)_____________________________________________ Fax (_____)__________________________________________ Email address _____________________________________________________________________________________________________ Specialty _________________________________________________________________________________________________________ Type of Practice: o Private o Academic o Hospital o Resident/Fellow Registration fee: $ 250 - Physicians $ 100 - Residents, Fellows, Nurses and Allied Health Professionals $ 300 - Industry Professionals Enclosed is my check in the i/a/o of _____ for registration of this course. I authorize MECC to charge my credit card i/a/o $______ for registration of this course using the following credit card. Name on Card ________________________________________________________________ Exp. Date ___________________________ Card number _________________________________________________________________ CVV ________________________________ Authorized signer __________________________________________________________________________________________________ If you require special assistance or have specific dietary requirements, please contact MECC, Inc. no later than January 4th, 2017 via email at [email protected].